Literature DB >> 33681829

Viral and serological testing of SARS-CoV-2 among health care workers and patients in Vietnam.

Le Huu Song1,2, Nghiem Xuan Hoan1,2, Mai Hong Bang1,2, Peter G Kremsner2,3,4, Thirumalaisamy P Velavan2,3.   

Abstract

Entities:  

Keywords:  COVID-19; HCW; Healthcare workers; Hospitalised; SARS-CoV-2 RNA; SARS-CoV-2 antibody; Seroprevalence; outpatients

Year:  2021        PMID: 33681829      PMCID: PMC7923908          DOI: 10.1016/j.lanwpc.2021.100113

Source DB:  PubMed          Journal:  Lancet Reg Health West Pac        ISSN: 2666-6065


× No keyword cloud information.
Vietnam reports a total of 1819 cases with 35 deaths (as on 02 February 2021), and transmission driven by clusters of cases [1]. A rapid, proactive and decisive government response in the early stages of the epidemic in identifying and delineating infection hotspots has led to effective case control management [2]. The sustainability of health systems is significantly challenged by the current COVID 19 pandemic, as frontline health care workers (HCWs) in patient-facing roles are at increased risk [3]. The aim of this single center hospital-based study was to describe the prevalence of SARS-CoV-2 by viral and serological testing in one of the largest hospitals in Vietnam, which serves 2000 hospitalized patients and approximately 4000 outpatients per day. The study was approved by the institutional review board of the 108 Military Central Hospital, Hanoi, Vietnam (108 MCH-Protocol number 02RES-CoV-3–2020). Between 01 March 2020 and 08 January 2021, we used a combination of RT-PCR assays to detect SARS-CoV-2 RNA and enzyme-linked immunosorbent assays to detect anti-SARS-CoV-2 immunoglobulins (IgM) and total antibodies (See supplementary material) among HCWs (n = 1519), hospitalised patients with respiratory illnesses (n = 838), outpatients with respiratory illnesses (n = 491) and attending outpatients for routine health-check (n = 8897). The median age of HCW was 33 years (range 20–60; 848 male), of respiratory patients 60 years (range 2–102; 811 male) and of outpatients 28 years (range 1–91; 5460 male). All HCWs and patients tested negative for SARS-CoV-2 for only one time point by RT-PCR. HCWs (n = 1065) and hospitalised patients (n = 288) who had previously tested negative for SARS-CoV-2 by RT-PCR were prospectively screened for seroprevalence of SARS-CoV-2 antibodies for one time point. Among the HCWs, three were positive for IgM (3/1065), six for total antibodies (6/1065), while all were negative by rapid diagnostic tests (RDT). All three IgM positives were negative for total antibodies and can be considered false positives as the titers were slightly above the cut-off value. All hospitalised patients admitted with respiratory illnesses were negative for SARS-CoV-2 antibodies (IgM, total antibodies and RDT). A possible explanation for this low prevalence observed in this study is a very low prevalence in the community accompanied by comprehensive staff education, patient triage and implementation of containment protocols in this hospital. HCWs represent a high-risk population for infection and identifying factors associated with SARS-CoV-2 infection and monitoring the seroprevalence can help stratify the HCWs in terms of risk, establish better practices and procedures in health facilities, to contain transmission.

Declaration of Competing Interest

All authors disclose no conflicts of interest.
  5 in total

1.  SARS-CoV-2 viral dynamics of the first 1000 sequences from Vietnam and neighbouring ASEAN countries.

Authors:  Nghiem Xuan Hoan; Srinivas Reddy Pallerla; Pham Xuan Huy; Hannah Krämer; Truong Nhat My; Tran Thanh Tung; Phan Quoc Hoan; Nguyen Linh Toan; Le Huu Song; Thirumalaisamy P Velavan
Journal:  IJID Reg       Date:  2022-01-20

2.  SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia.

Authors:  Jessica Manning; Irfan Zaidi; Chanthap Lon; Luz Angela Rosas; Jae-Keun Park; Aiyana Ponce; Jennifer Bohl; Sophana Chea; Maria Karkanitsa; Sokunthea Sreng; Huy Rekol; Char Meng Chour; Dominic Esposito; Jeffery K Taubenberger; Matthew J Memoli; Kaitlyn Sadtler; Patrick E Duffy; Fabiano Oliveira
Journal:  Emerg Infect Dis       Date:  2022-02       Impact factor: 6.883

3.  Pre-pandemic SARS-CoV-2 serological reactivity in rural malaria-experienced Cambodians.

Authors:  Jessica Manning; Irfan Zaidi; Chanthap Lon; Luz Angela Rosas; Jae-Keun Park; Aiyana Ponce; Jennifer Bohl; Sophana Chea; Maria Karkanitsa; Sokunthea Sreng; Huy Rekol; Char Meng Chour; Dominic Esposito; Jeffery K Taubenberger; Matthew J Memoli; Kaitlyn Sadtler; Patrick E Duffy; Fabiano Oliveira
Journal:  medRxiv       Date:  2021-09-28

4.  SARS-CoV-2 seroprevalence in Mongolia: Results from a national population survey.

Authors:  Battogtokh Chimeddorj; Undram Mandakh; Linh-Vi Le; Batzorig Bayartsogt; Zolzaya Deleg; Oyunsuren Enebish; Oyunbaatar Altanbayar; Battur Magvan; Anuujin Gantumur; Otgonjargal Byambaa; Gerelmaa Enebish; Bat-Erdene Saindoo; Mandakhnaran Davaadorj; Avarzed Amgalanbaatar; Khangai Enkhtugs; Usukhbayar Munkhbayar; Batkhuu Bayanjargal; Tuyajargal Badamsambuu; Myagmartseren Dashtseren; Zolmunkh Narmandakh; Khongorzul Togoo; Enkh-Amar Boldbaatar; Ariunzaya Bat-Erdene; Yerkyebulan Mukhtar; Oyu-Erdene Shagdarsuren; Mandukhai Ganbat; Ochbadrakh Batjargal; Bayasgalantai Bavuusuren; Batzaya Batchuluun; Gereltsetseg Zulmunkh; Ganbaatar Byambatsogt; Khurelbaatar Nyamdavaa; Tserendagva Dalkh; Damdindorj Boldbaatar; Tuvshinjargal Tseren; Darambazar Gantulga; Otgonbayar Damdinbazar; Byambasuren Vanchin; Lorenzo Subissi; Isabel Bergeri; Davaalkham Dambadarjaa; Nymadawa Pagbajabyn; Gregory Greif; Ryenchindorj Erkhembayar
Journal:  Lancet Reg Health West Pac       Date:  2021-11-23

5.  Seroprevalence of SARS-CoV-2 among high-density communities and hyper-endemicity of COVID-19 in Vietnam.

Authors:  Van Thuan Hoang; Thi Dung Pham; Quoc Tien Nguyen; Duy Cuong Nguyen; Duc Thanh Nguyen; Thanh Binh Nguyen; Thi Khanh Thu Tran; Trong Lan Phan; Phan Le Nguyen Vo; Thi Loi Dao; Florence Fenollar; Philippe Gautret
Journal:  Trop Med Int Health       Date:  2022-03-25       Impact factor: 3.918

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.